BFRI on Nasdaq
Biofrontera Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Verona Pharma, Equillium, Inc. or Wave Life Sciences, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-27.2%Operating margin3
-25.3%Net margin3
11.7%Revenue growth, 20253
-100.5%Return on equity3
-$13.4MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development9¢$3.7M
- Selling, general and admin91¢$37.8M
- Other costs1¢$210.0K
- Income tax0¢$25.0K
Out of $41.7M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Product revenues, net | $41.7M | $37.3M |
| Revenues, related party | $18.0K | |
| Total revenues, net | $41.7M | $37.3M |
| Selling, general and administrative | $37.8M | $33.8M |
| Selling, general and administrative, related party | $619.0K | $42.0K |
| Research and development | $3.7M | $2.1M |
| Total operating expenses | $53.1M | $54.5M |
| Loss from operations | -$11.3M | -$17.2M |
| Change in fair value of warrant liabilities | $899.0K | $1.7M |
| Change in fair value of investment, related party | $2.0K | -$14.0K |
| Loss on debt extinguishment | -$316.0K | |
| Interest expense, net | -$452.0K | -$2.0M |
| Other income, net | $388.0K | $158.0K |
| Total other income (expense) | $837.0K | -$527.0K |
| Loss before income taxes | -$10.5M | -$17.7M |
| Income tax expense | $25.0K | $22.0K |
| Net loss | -$10.5M | -$17.8M |
| Basic | -$1.04 | -$3.22 |
| Diluted | -$1.04 | -$3.22 |
| Basic | 10.2M shares | 5.5M shares |
| Diluted | 10.2M shares | 5.5M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $6.4M | $5.9M | |
| Investment, related party | $9.0K | $7.0K | |
| Accounts receivable, net | $7.3M | $5.3M | |
| Inventories | $1.4M | $6.6M | |
| Prepaid expenses and other current assets | $2.3M | $527.0K | |
| Asset held for sale | $2.3M | ||
| Total current assets | $18.1M | $20.7M | |
| Inventories, long term | $3.7M | ||
| Property and equipment, net | $2.2M | $80.0K | |
| Operating lease right-of-use assets | $1.6M | $903.0K | |
| Intangible assets, net | $2.6M | $35.0K | |
| Other assets | $360.0K | $383.0K | |
| Total assets | $28.6M | $22.1M | |
| Operating lease liabilities | $332.0K | $548.0K | |
| Accrued expenses and other current liabilities | $4.9M | $4.3M | |
| Total current liabilities | $11.9M | $12.0M | |
| Convertible notes payable | $4.6M | $4.1M | |
| Warrant liabilities | $351.0K | $1.2M | |
| Operating lease liabilities, non-current | $1.2M | $276.0K | |
| Other liabilities | $9.0K | $23.0K | |
| Total liabilities | $18.1M | $17.7M | |
| Common Stock, $0.001 par value, 70,000,000 shares authorized; 11,648,323 and 8,873,932 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $12.0K | $9.0K | |
| Additional paid-in capital | $138.4M | $121.8M | |
| Accumulated deficit | -$127.9M | -$117.4M | |
| Total stockholders equity | $10.5M | $4.4M | |
| Total liabilities and stockholders equity | $28.6M | $22.1M | |
| Preferred stock par value, per share | $0.00 | $0.00 | $0.00 |
| Preferred stock, shares authorized | 20.0M shares | 20.0M shares | 20.0M shares |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 70.0M shares | 70.0M shares | 70.0M shares |
| Common stock, shares issued | 11.6M shares | 8.9M shares | |
| Common stock, shares outstanding | 11.6M shares | 8.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$10.5M | -$17.8M |
| Depreciation and amortization | $138.0K | $421.0K |
| Reduction in the carrying amount of right-of-use assets | $730.0K | $728.0K |
| Stock-based compensation | $951.0K | $1.0M |
| Non-cash interest expense | $491.0K | $297.0K |
| Allowance for credit losses | -$69.0K | $162.0K |
| Change in fair value of warrant liabilities | -$899.0K | -$1.7M |
| Gain on sale of asset held for sale | -$700.0K | |
| Loss from termination of operating leases | $19.0K | |
| Realized/unrealized loss in investment, related party | -$2.0K | $14.0K |
| Loss on debt extinguishment | $316.0K | |
| Accounts receivable | -$1.9M | -$315.0K |
| Other receivables, related party | $2.0K | |
| Prepaid expenses and other assets | -$1.7M | -$141.0K |
| Other assets, related party | -$686.0K | $5.2M |
| Inventories | $1.4M | $4.2M |
| Accounts payable | -$2.0K | -$1.5M |
| Accounts payable, related parties, net | -$533.0K | -$355.0K |
| Operating lease liabilities | -$683.0K | -$689.0K |
| Accrued expenses and other liabilities | $610.0K | -$230.0K |
| Cash flows used in operating activities | -$13.4M | -$10.3M |
| Proceeds from sale of asset held for sale | $3.0M | |
| Sales of investment, related party | $57.0K | |
| Purchase of intangible assets | -$50.0K | |
| Purchases of property and equipment | -$2.0K | -$10.0K |
| Cash flows provided by (used in) investing activities | $3.0M | -$3.0K |
| Proceeds from issuance of Series C preferred stock, net of offering costs | $10.8M | |
| Proceeds from issuance of Series B-1 preferred stock and warrants to purchase series B-3 preferred stock, net of issuance costs | $7.7M | |
| Proceeds from issuance of Series B-3 preferred stock from exercise of warrants | $7.4M | |
| Proceeds from issuance of convertible notes, net of issuance costs | $4.0M | |
| Payment of principal short-term debt | -$4.3M | |
| Cash flows provided by financing activities | $10.8M | $14.8M |
| Net increase in cash and cash equivalents | $487.0K | $4.6M |
| Interest paid | $6.0K | $1.7M |
| Income tax paid, net | $25.0K | $24.0K |
| Preferred stock issued as consideration in asset purchase acquisition (See Note 3. Asset Acquisition) | $4.8M | |
| Property, plant and equipment acquired | $2.1M | |
| Intangible asset acquired | $2.7M | |
| Addition of right-of-use assets in exchange for operating lease liabilities | $1.4M | $55.0K |
Recent filings
- Sep 14, 20268-K
- Aug 13, 20268-K
- Aug 13, 202610-Q
- Aug 12, 2026SCHEDULE 13G/A
- Jul 29, 20264
- Jul 29, 20264
- Jul 22, 202610-K/A
- Jul 22, 2026S-8
- Jun 17, 20268-K
- May 14, 20268-K
- May 14, 202610-Q
- Apr 30, 2026DEF 14A
- Mar 19, 20268-K
- Mar 19, 202610-K
- Mar 9, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9